Potential Role for HIV-specific CD38-/HLA-DR+ CD8+ T Cells in Viral Suppression and Cytotoxicity in HIV Controllers

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Jul 8

PMID 25000587

Citations 42

Authors

Stephane Hua

Camille Lecuroux

Asier Saez-Cirion

Gianfranco Pancino

Isabelle Girault

Pierre Versmisse

Faroudy Boufassa

Olivier Taulera

Martine Sinet

Olivier Lambotte

Alain Venet

Affiliations

Soon will be listed here.

Abstract

Background: HIV controllers (HIC) are rare HIV-1-infected patients who exhibit spontaneous viral control. HIC have high frequency of CD38-/HLA-DR+ HIV-specific CD8+ T cells. Here we examined the role of this subset in HIC status.

Materials And Methods: We compared CD38-/HLA-DR+ CD8+ T cells with the classical CD38+/HLA-DR+ activated phenotype in terms of 1) their activation status, reflected by CD69, CD25, CD71, CD40 and Ki67 expression, 2) functional parameters: Bcl-2 expression, proliferative capacity, and IFN-γ and IL-2 production, and 3) cytotoxic activity. We also investigated how this particular profile is generated.

Results: Compared to CD38+/HLA-DR+ cells, CD38-/HLA-DR+ cells exhibited lower expression of several activation markers, better survival capacity (Bcl-2 MFI, 367 [134-462] vs 638 [307-747], P = 0.001), higher frequency of polyfunctional cells (15% [7%-33%] vs 21% [16%-43%], P = 0.0003), greater proliferative capacity (0-fold [0-2] vs 3-fold [2]-[11], P = 0.007), and higher cytotoxicity in vitro (7% [3%-11%] vs 13% [6%-22%], P = 0.02). The CD38-/HLA-DR+ profile was preferentially generated in response to low viral antigen concentrations.

Conclusions: These data highlight the role of CD38-/HLA-DR+ HIV-specific CD8+ T cell cytotoxicity in HIC status and provide insights into the mechanism by which they are generated. Induction of this protective CD8+ subset may be important for vaccine strategies.

Citing Articles

HIV-1 Elite Controllers Are Characterized by Elevated Levels of CD69-Expressing Natural Killer Cells.

Batohi N, Shalekoff S, Shalekoff S, Martinson N, Ebrahim O, Tiemessen C J Acquir Immune Defic Syndr. 2024; 97(5):522-532.

PMID: 39219024 PMC: 11540281. DOI: 10.1097/QAI.0000000000003518.

Autoimmunity-associated allele of tyrosine phosphatase gene PTPN22 enhances anti-viral immunity.

Orozco R, Marquardt K, Pratumchai I, Shaikh A, Mowen K, Domissy A PLoS Pathog. 2024; 20(3):e1012095.

PMID: 38512979 PMC: 10987006. DOI: 10.1371/journal.ppat.1012095.

Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism.

Huang Y, Shao M, Teng X, Si X, Wu L, Jiang P Cell Rep Med. 2024; 5(2):101400.

PMID: 38307031 PMC: 10897548. DOI: 10.1016/j.xcrm.2024.101400.

Impact of the immune profiles of hypertensive patients with and without obesity on COVID-19 severity.

Moll-Bernardes R, Ferreira J, Sousa A, Tortelly M, Pimentel A, Figueiredo A Int J Obes (Lond). 2023; 48(2):254-262.

PMID: 37932408 DOI: 10.1038/s41366-023-01407-0.

Dynamic changes of the proportion of HLA-DR and CD38 coexpression subsets on T lymphocytes during IFN-based chronic hepatitis B treatment.

Lin Y, Shen G, Xie S, Bi X, Lu H, Yang L Front Immunol. 2023; 13:1116160.

PMID: 36761161 PMC: 9902929. DOI: 10.3389/fimmu.2022.1116160.

References

Brenchley J, Price D, Schacker T, Asher T, Silvestri G, Rao S . Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12(12):1365-71. DOI: 10.1038/nm1511. View

Migueles S, Osborne C, Royce C, Compton A, Joshi R, Weeks K . Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity. 2008; 29(6):1009-21. PMC: 2622434. DOI: 10.1016/j.immuni.2008.10.010. View

Saez-Cirion A, Shin S, Versmisse P, Barre-Sinoussi F, Pancino G . Ex vivo T cell-based HIV suppression assay to evaluate HIV-specific CD8+ T-cell responses. Nat Protoc. 2010; 5(6):1033-41. DOI: 10.1038/nprot.2010.73. View

Sandoval-Montes C, Santos-Argumedo L . CD38 is expressed selectively during the activation of a subset of mature T cells with reduced proliferation but improved potential to produce cytokines. J Leukoc Biol. 2004; 77(4):513-21. DOI: 10.1189/jlb.0404262. View

Deeks S, Kitchen C, Liu L, Guo H, Gascon R, Narvaez A . Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood. 2004; 104(4):942-7. DOI: 10.1182/blood-2003-09-3333. View

Deeks S, Walker B . Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity. 2007; 27(3):406-16. DOI: 10.1016/j.immuni.2007.08.010. View

Betts M, Price D, Brenchley J, Lore K, Guenaga F, Smed-Sorensen A . The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration. J Immunol. 2004; 172(10):6407-17. DOI: 10.4049/jimmunol.172.10.6407. View

Sachdeva M, Fischl M, Pahwa R, Sachdeva N, Pahwa S . Immune exhaustion occurs concomitantly with immune activation and decrease in regulatory T cells in viremic chronically HIV-1-infected patients. J Acquir Immune Defic Syndr. 2010; 54(5):447-54. PMC: 3095513. DOI: 10.1097/QAI.0b013e3181e0c7d0. View

Migueles S, Laborico A, Shupert W, Sabbaghian M, Rabin R, Hallahan C . HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol. 2002; 3(11):1061-8. DOI: 10.1038/ni845. View

10.

Herbeuval J, Nilsson J, Boasso A, Hardy A, Kruhlak M, Anderson S . Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. Proc Natl Acad Sci U S A. 2006; 103(18):7000-5. PMC: 1444883. DOI: 10.1073/pnas.0600363103. View

11.

Okulicz J, Marconi V, Landrum M, Wegner S, Weintrob A, Ganesan A . Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis. 2009; 200(11):1714-23. DOI: 10.1086/646609. View

12.

Carrington M, Walker B . Immunogenetics of spontaneous control of HIV. Annu Rev Med. 2012; 63:131-45. PMC: 3725592. DOI: 10.1146/annurev-med-062909-130018. View

13.

Hunt P, Brenchley J, Sinclair E, McCune J, Roland M, Page-Shafer K . Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008; 197(1):126-33. PMC: 3466592. DOI: 10.1086/524143. View

14.

Carrington M, OBrien S . The influence of HLA genotype on AIDS. Annu Rev Med. 2003; 54:535-51. DOI: 10.1146/annurev.med.54.101601.152346. View

15.

Bourgeois C, Rocha B, Tanchot C . A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science. 2002; 297(5589):2060-3. DOI: 10.1126/science.1072615. View

16.

Goulder P, Walker B . HIV and HLA class I: an evolving relationship. Immunity. 2012; 37(3):426-40. PMC: 3966573. DOI: 10.1016/j.immuni.2012.09.005. View

17.

Doisne J, Urrutia A, Lacabaratz-Porret C, Goujard C, Meyer L, Chaix M . CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J Immunol. 2004; 173(4):2410-8. DOI: 10.4049/jimmunol.173.4.2410. View

18.

Berger C, Frahm N, Price D, Mothe B, Ghebremichael M, Hartman K . High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control. J Virol. 2011; 85(18):9334-45. PMC: 3165743. DOI: 10.1128/JVI.00460-11. View

19.

Speiser D, Migliaccio M, Pittet M, Valmori D, Lienard D, Lejeune F . Human CD8(+) T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells. Eur J Immunol. 2001; 31(2):459-66. DOI: 10.1002/1521-4141(200102)31:2<459::aid-immu459>3.0.co;2-y. View

20.

Pereyra F, Palmer S, Miura T, Block B, Wiegand A, Rothchild A . Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis. 2009; 200(6):984-90. PMC: 3725728. DOI: 10.1086/605446. View